Evolution of the HMG CoA reductase inhibitors (statins) in cardiovascular medicine

British Journal of Cardiology

Volumn 11, Issue 2, 2004, Pages 129-136

  Packard, Christopher J ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Coronary heart disease; Dyslipidaemia; Lipids; Primary care; Statins; Type 2 diabetes

Indexed keywords

ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG USE; DYSLIPIDEMIA; ELDERLY CARE; EVIDENCE BASED MEDICINE; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIVER DYSFUNCTION; METABOLIC SYNDROME X; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PROSPECTIVE STUDY; RHABDOMYOLYSIS; RISK REDUCTION; VASCULAR DISEASE;

EID: 1942519771     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Stamler J, Wentworth G, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Finding in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
2. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-07.
3. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-09.
6. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
7. Athyros V, Papageorgiou A, Mercouris B et al. Treatment with atorvastatin to the National Cholesterol Education Program Goals versus 'usual care' in secondary coronary heart disease prevention: The Greek Atorvastatin and Coronary Heart disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22 and 23-33.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
10. Goldberg RB, Mellies MJ, Sacks FM et al. for the CARE Investigators. Cardiovascular event and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the Cholesterol And Recurrent Events (CARE) trial. Circulation 1998;98:2513-19.
11. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
12. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
13. Wood D, De Backer G, Faergeman O et al. Recommendations of the second joint task force of European and other societies on coronary prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998;19:1434-503.
14. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Lancet 2001;357:995-1001.
15. Reid FDA, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002; 88:15-19.
16. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey BMJ 2000;321:322-5.
17. Andrade SE, Walker AM, Gottlieb LK et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31.
18. Wei L, Wang J, Thompson P et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229-33.
19. Benner JS, Glynn RJ, Mogun H et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
20. Knatterud GL, Rosenberg Y, Campeau L et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000;102:157-65.
21. Hanfeld M. Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor. Int J Clin Pract 2001;55:399-405.
22. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341: 498-511.
23. Olsson AG, McTaggart F, Raza A. Rosuvastatin. A highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303-28.
24. Smith G, Davidson R, Bloor S et al. Pharmacological properties of ZD4522: a new HMGCoA reductase inhibitor. Atherosclerosis 2000;151:39 (abstract).
25. Warwick MJ, Dane AI, Schneck DW et al. Single and multiple dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis 2000;151:39(abstract).
26. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning and evening administration in healthy volunteers. Br J Clin Pharmacol 2002;54:472-7.
27. Nezasa K, Higaki K, Hasegawa H et al. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat. Atherosclerosis 2000;151:39 (abstract).
28. McTaggart F, Buckett L, Davidson R et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-2-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87(suppl):28B-32B.
29. McCormick AD, McKillop D, Butters CJ et al. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems. J Clin Pharmacol 2000,40: 1055.
30. Department of Health. National Service Framework for coronary heart disease: modern standards and service models. London: The Stationery Office, 2000. Available at: www.doh.gov.uk/nsf/coronary.htm
31. Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol 2000;74(suppl 1):S23-8.
32. Shepherd J, Hunninghake DB, Barter P et al. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003;91(suppl):11C-19C.
33. Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003;91(suppl):3C-10C.
34. Austin MA, King MC, Vranizan KM et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
35. Campos H, Blijlevens E, McNamara JR et al. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb 1992;12:1410-19,
36. Austin MA, Selby JV. LDL subclass phenotypes and the risk factors of the insulin resistance syndrome. Int J Obes Relat Metab Disord 1995; May(suppl 1):S22-6.
37. Lamarce B, Tchernof A, Morrjani S et al. Small, dense low-density lipoprotein particles as a predictor of ischaemic heart disease in men. Circulation 1997;95:69-75.
38. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66B-69B.
39. Bradley WA, Hwang SLC, Karlin JB et al. Low density receptor binding determinants switch from apoliprotein E to apolipoprotein B during conversion of hypertriglyceridemic low density lipoproteins to low density lipoproteins. J Biol Chem 1984;259:14728-35.
40. Huff MW, Burnett JR. 3-hydroxy-3-methylglutaryl coenzyme A inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipidol 1997;8:138-45.
41. Forster LF, Stewart G, Bedford D et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidaemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 2002;164:129-45.
42. Guerin M, Lassel TS, Le Goff W et al. Action of atorvastatin in combined hyperlipidaemia: preferential reduction of cholesterol ester transfer protein from HDL to VLDL particles. Arterioscler Thromb Vasc Biol 2000;20: 189-97.
43. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:81-6.
44. Superko HR. What can we learn about dense low density lipoprotein and lipoprotein particles from clinical trials? Curr Opin Lipidol 1996;7:363-8.
45. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5:339-49.
46. Tribble DL, Holl LG, Wood PD et al. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992;93:189-99.
47. Packard C, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arter Throm Vasc Biol 1997;17:3542-56.
48. Feher MD, Caslake M, Foxton J et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999;15:395-9.
49. Zambon S, Cortella A, Sartore G et al. Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size. Eur J Clin Pharmacol 1994;46:221-4.
50. Guerin M, Egger P, Soudant C et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 2002;163:287-96.
51. Caslake MJ, McTaggart F, Chapman MJ et al. Phenotype dependent and independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 2003;171:245-53.
52. Jacobs DR, Mebane IL, Bangdiwala SI et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990;131:32-47.
53. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15.
54. Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.
55. Streja L, Packard CJ, Shepherd J et al. for the WOSCOPS group. Factors affecting low-density and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 2002;90:731-6.
56. Asztalos BT, Horvath KV, McNamara JR et al. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002;164:361-9.
57. Illingworth DR, Crouse JR 3rd, Hunninghake DB et al. for the Simvastatin Atorvastatin HDL Study Group. A comparison of +simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 2001;17:43-50.
58. Stein E, Strutt KL, Miller E et al. Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis Supplements 2001;2:90-1(Abs P176).
59. Hannuksela M, Marcel YL, Kesaniemi YA et al. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res 1992;33:737-44.
60. Bradford RH, Shear CL, Chremos AN et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
61. Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs 2001;61:197-206.
62. Stein A. Laboratory surrogates for anti-atherosclerosis drug development. Am J Cardiol 2001;87(suppl):21A-26A.
63. Pfeffer MA, Keech A, Sacks FM et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105:2341-6.
64. The LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002;359:1379-87.
65. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998;158:577-84.
66. Insull W Jr, Isaacsohn J, Kwiterovich P et al. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. J Int Med Res 2000;28:47-68.
67. Farmer JA. Lessons learnt from the cerivastatin experience. Lancet 2001;358:1383-5.
68. Department of Health. National Service Framework: diabetes. London: The Stationery Office, 2002. Available at: www.doh.gov.uk/nsf/diabetes